Jerusalem-based Oramed Pharmaceuticals Inc., a developer of oral delivery systems, announced that it is the recipient of the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award.

"We are honored to receive the 2009 European Oral Drug Delivery Technology Innovation Award," said Nadav Kidron, Esq., Oramed's CEO. "Being recognized for our leadership position in the oral drug delivery field by Frost & Sullivan is an encouraging validation of our progress."

Oramed Pharmaceuticals is developing a platform technology to create oral delivery systems for drugs and vaccines delivered via injection. Oramed focuses on the treatment of diabetes through its proprietary flagship product, an Oral Insulin capsule that is currently in Phase 2b clinical trials. Oramed's research pipeline also includes other product candidates, such as an Oral GLP-1 Analog capsule.

Frost & Sullivan's Technology Innovation Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices in the industry.

Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center.